models

Start with patient samples already containing specific disease relevant mutations and iPSC technology to reprogram into stem cell lines OR in-house control cell stem cell lines in which we use CRISPR-Cas9 technology to introduce relevant mutations

Using our proprietary protocols we convert the stem cell lines into distinct neuronal populations, generating stocks of billions of neurons

Neuronal stocks undergo robust quality control measure before cryopreservation to ensure reproducibility